Core areas
Novo Nordisk an international company
Novo Nordisk's organization
Novo Nordisk key figures

It is Novo Nordisk's business to develop and market products which satisfy real needs improving the way people live and work.
It is our business to find new and better ways to eliminate the threats and burdens of disease and to bring sustainable progress to industry and agriculture.

(From Novo Nordisk Vision 21)

Core areas
Novo Nordisk's core business areas are Diabetes Care, Women's Health Care (hormone replacement therapy), Human Growth Hormone and Industrial Enzymes. Novo Nordisk is the world's leading supplier of insulin and industrial enzymes and also markets a number of other products, such as pharmaceuticals to treat disorders of the central nervous system.

As part of Novo Nordisk's strategy to focus on the above core areas, Ferrosan A/S and the biological plant protection business were sold in 1995. At the beginning of 1996 the company signed a declaration of intent to sell the Plasma Product Unit and announced the decision to close down the enzyme factory on Hokkaido, Japan, and the bulk penicillin factory in Anagni, Italy.

Novo Nordisk an international company
Headquartered in Denmark, Novo Nordisk has companies and information offices in 54 countries and production facilities in seven countries. Novo Nordisk is a biotechnological company where the basic production method is fermentation. Novo Nordisk has fermentation capacity in Denmark, the USA, Switzerland and Brazil. A new enzyme factory is being constructed in Tianjin, China. The factory will employ around 300 people and is expected to become operational during 1998.

At the end of 1995 12,997 people were employed by Novo Nordisk, of whom approx. 2,900 in research, 5,900 in production, and 4,200 in sales, marketing and administration.

Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen, London, Basel, Zürich and Geneva, and on the New York Stock Exchange.

Novo Nordisk's A shares are all held by the Novo Nordisk Foundation, a private foundation which grants financial support to scientific, humanitarian and social objectives. The Foundation also owns B shares, thus holding 25.1% of the total share capital and controlling 67.3% of the total number of votes.


NOVO NORDISK KEY FIGURES 1991 1992 1993 1994 1995

Net turnover (DKK million)
Health Care Business 6,382 7,084 8,225 9,236 9,934
Enzyme Business 2,400 2,819 3,202 3,472 3,388
Other business areas 579 796 736 816 401
Total net turnover 9,361 10,699 12,163 13,524 13,723

Development in volume/product mix
(Turnover adjusted for currency/price fluctuations)
Health Care Business 10% 15% 12% 11% 14%
Enzyme Business 22% 21% 12% 14% 8%

Investments (DKK million) 1,348 1,957 2,392 1,738 1,212

Research and development costs (DKK million) 1,347 1,522 1,669 1,896 1,950

Number of employees 9,627 10,733 11,648 12,847 12,997

Menu Next